中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
17期
88-89
,共2页
老年急性白血病%参麦注射液%化学治疗
老年急性白血病%參麥註射液%化學治療
노년급성백혈병%삼맥주사액%화학치료
senile acute leukemia%Shenmai Injection%chemotherapy
目的：探讨提高治疗老年急性白血病有效性的方法。方法将78例患者随机分为观察组和对照组，各39例。观察组采用CAG和参麦注射液治疗，对照组只采用 CAG方案。结果观察组总有效率为87.18%，明显高于对照组的84.62%(χ2=0.519，P=0.820＞0.05)。两组患者组间与组内在白细胞、血红蛋白指标上无显著性差异( P＞0.05)，而在红细胞、血小板指标上存在显著性差异(χ2=6.639，P<0.05；χ2=6.587，P<0.05)。两组患者临床毒副反应方面存在显著性差异( P<0.05)。结论 CAG方案联合参麦注射液对老年急性白血病具有良好的疗效。临床治疗时需对年龄偏高和免疫力低下的患者缩减用量，同时注重护理和感染防护等，以提高疗效、延长患者的生存期。
目的：探討提高治療老年急性白血病有效性的方法。方法將78例患者隨機分為觀察組和對照組，各39例。觀察組採用CAG和參麥註射液治療，對照組隻採用 CAG方案。結果觀察組總有效率為87.18%，明顯高于對照組的84.62%(χ2=0.519，P=0.820＞0.05)。兩組患者組間與組內在白細胞、血紅蛋白指標上無顯著性差異( P＞0.05)，而在紅細胞、血小闆指標上存在顯著性差異(χ2=6.639，P<0.05；χ2=6.587，P<0.05)。兩組患者臨床毒副反應方麵存在顯著性差異( P<0.05)。結論 CAG方案聯閤參麥註射液對老年急性白血病具有良好的療效。臨床治療時需對年齡偏高和免疫力低下的患者縮減用量，同時註重護理和感染防護等，以提高療效、延長患者的生存期。
목적：탐토제고치료노년급성백혈병유효성적방법。방법장78례환자수궤분위관찰조화대조조，각39례。관찰조채용CAG화삼맥주사액치료，대조조지채용 CAG방안。결과관찰조총유효솔위87.18%，명현고우대조조적84.62%(χ2=0.519，P=0.820＞0.05)。량조환자조간여조내재백세포、혈홍단백지표상무현저성차이( P＞0.05)，이재홍세포、혈소판지표상존재현저성차이(χ2=6.639，P<0.05；χ2=6.587，P<0.05)。량조환자림상독부반응방면존재현저성차이( P<0.05)。결론 CAG방안연합삼맥주사액대노년급성백혈병구유량호적료효。림상치료시수대년령편고화면역력저하적환자축감용량，동시주중호리화감염방호등，이제고료효、연장환자적생존기。
Objective To research the method for improving the effectiveness in treating senile acute leukemia. Methods 78 patients with senile acute leukemia were divided into the observation group and the control group with 39 cases in each group. The observation group was treated with the CAG scheme combined with Shenmai Injection, while the control group only adopted the CAG scheme. The clinical data after treatment in the two groups were statistically analyzed. Results The total effective rate after treatment was 87. 18%in the observation group, which was obviously higher than 84. 62% in the control group, but the difference between the two groups had no statistical significance (χ2=0. 519, P=0. 820> 0. 05 ) . Moreover, no statistically significant differences in the indexes of WBC and hemoglobin were found between the two groups ( P>0. 05 ) , while the indexes of RBC and platelet had statistically significantly differ-ences (χ2=6. 639, P<0. 05, χ2=6. 587, P<0. 05 ) . The two groups had statistically significant differences in the aspect of clinical toxic and side effects ( P<0. 05 ) . Conclusion The CAG scheme combined Shenmai Injection has a good therapeutic effect in treating senile acute leukemia. In the clinical treatment, the dosage should be decreased for the patients with high age and hypoimmunity. At the same time more attention should be paid to the nursing care and infection prevention in order to improve the therapeutic effect and prolong the survival period of patients.
